Summary

Niraparib is a potent oral PARP1 and PARP2 (poly [ADP-ribose] polymerase) inhibitor with antitumor activity in germline BRCA mutation (gBRCAmut) ovarian cancer and BRCA-negative (non-gBRCAmut) high-grade serous ovarian cancer (HGSOC). This article presents the study design of an ongoing niraparib maintenance study examining platinum-sensitive patients with ovarian cancer and deleterious gBRCAmut or high-grade serous histology non-gBRCAmut [NOVA; NCT01847274].